Experience matters in TAVR outcomes, a new international registry study finds, providing fodder to the ongoing debate about the need for procedural volume requirements for TAVR programs. A learning ...
Edwards Lifesciences (EW) announced results from the EARLY TAVR Trial, the first randomized, controlled trial designed to study the best strategy for treating asymptomatic severe aortic stenosis and ...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy ...
New European data are offering reassurance that patients already taking an anticoagulant can continue taking their meds when they undergo TAVR, without needing to stop and bridge or increasing their ...
Medtronic plc MDT recently secured the FDA’s approval for the Evolut FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The latest Evolut ...
SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results